Finerenone in Diabetic Chronic Kidney Disease—Real-World Insights Including Patients with HFpEF or HFmrEF
In a real-world setting, treatment with finerenone is safe and well-tolerated in patients with DKD and may improve functional and structural cardiac parameters. Further investigation is warranted.
Authors
- Fani Delistefani
- Michael Koziolek (ORCID: https://orcid.org/0000-0002-0897-5430)
- Ann‐Kathrin Schäfer (ORCID: https://orcid.org/0000-0003-2676-9670)
- Manuel Wallbach (ORCID: https://orcid.org/0000-0002-1162-4682)
- Stephan von Hörsten (ORCID: https://orcid.org/0000-0001-6409-0664)
- Kristian Hellenkamp
- Miroslava Valentová (ORCID: https://orcid.org/0000-0001-8622-0810)
- Katja Gollisch (ORCID: https://orcid.org/0000-0001-8266-6516)
- Dirk Raddatz (ORCID: https://orcid.org/0000-0002-9509-4462)
- Sophia Kaebe
Institutions
- Universitätsmedizin Göttingen (DE)
- German Centre for Cardiovascular Research (DE)
- University of Göttingen (DE)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1002/ehf2.15424
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00